cemiplimab   

GtoPdb Ligand ID: 10090

Synonyms: cemiplimab-rwlc | Libtayo® | REGN-2810 | REGN2810 | SAR-439684 | SAR439684
cemiplimab is an approved drug (FDA (2018), EMA (2019))
Compound class: Antibody
Comment: Cemiplimab (REGN2810) is a fully human anti-PD-1 immuno-oncology biological therapeutic that was developed by Regeneron Pharmaceuticals [1-2]. This antibody was produced using Regeneron's genetically engineered VelocImmune® mice which have humanized immunoglobulin gene loci and produce human:mouse hybrid antibodies that can rapidly be converted to fully human antibodies [4].
Full peptide sequence and disulphide bond information is available from the IMGT/mAb-DB entry for this antibody.
Classification
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (FDA (2018), EMA (2019))
International Nonproprietary Names
INN number INN
10691 cemiplimab
Synonyms
cemiplimab-rwlc | Libtayo® | REGN-2810 | REGN2810 | SAR-439684 | SAR439684
Database Links
Specialist databases
IMGT/mAb-DB 846
Other databases
GtoPdb PubChem SID 381118800
Search PubMed clinical trials cemiplimab
Search PubMed titles cemiplimab
Search PubMed titles/abstracts cemiplimab